E
Ewald van Dyk
Researcher at Netherlands Cancer Institute
Publications - 5
Citations - 1502
Ewald van Dyk is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Comparative genomic hybridization & Breast cancer. The author has an hindex of 4, co-authored 4 publications receiving 1084 citations.
Papers
More filters
Journal ArticleDOI
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio,Francesco Iorio,Theo A. Knijnenburg,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Michael P. Menden,Michael Schubert,Nanne Aben,Nanne Aben,Emanuel Gonçalves,Syd Barthorpe,Howard Lightfoot,Thomas Cokelaer,Thomas Cokelaer,Patricia Greninger,Ewald van Dyk,Han Chang,Heshani de Silva,Holger Heyn,Xianming Deng,Regina K. Egan,Qingsong Liu,Tatiana Mironenko,Xeni Mitropoulos,Laura Richardson,Jinhua Wang,Tinghu Zhang,Sebastian Moran,Sergi Sayols,Maryam Soleimani,David Tamborero,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Petra Ross-Macdonald,Manel Esteller,Manel Esteller,Nathanael S. Gray,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +48 more
TL;DR: It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.
Journal ArticleDOI
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms
Philip C. Schouten,Anita Grigoriadis,Thomas Kuilman,Hasan Mirza,Johnathan Watkins,Saskia A. Cooke,Ewald van Dyk,Tesa M. Severson,Oscar M. Rueda,Marlous Hoogstraat,Caroline V.M. Verhagen,Rachael Natrajan,Suet-Feung Chin,Esther H. Lips,Janneke Kruizinga,Arno Velds,Marja Nieuwland,Ron M. Kerkhoven,Oscar Krijgsman,Conchita Vens,Daniel S. Peeper,Petra M. Nederlof,Carlos Caldas,Andrew Tutt,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Sabine C. Linn,Sabine C. Linn +27 more
TL;DR: Whether this classification can be reliably obtained with next generation sequencing and copy number platforms other than the bacterial artificial chromosome (BAC) array Comparative Genomic Hybridization (aCGH) on which it was originally developed is investigated.
Journal ArticleDOI
Platform comparisons for identification of breast cancers with a BRCA-like copy number profile
Philip C. Schouten,Ewald van Dyk,Linde M. Braaf,Lennart Mulder,Esther H. Lips,Jorma J. de Ronde,Laura Holtman,Jelle Wesseling,Michael Hauptmann,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Sabine C. Linn,Petra M. Nederlof +12 more
TL;DR: It is shown that breast cancer patients with BRCA-like tumour aCGH profiles benefit substantially from platinum-based chemotherapy, potentially due to their inability to repair DNA double strand breaks (DSB), providing a further important clinical application for the classifiers.
Journal ArticleDOI
IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.
Olga S. Blomberg,Lorenzo Spagnuolo,Hannah Claire Garner,Leonie Voorwerk,Olga I Isaeva,Ewald van Dyk,Noor A. M. Bakker,Myriam Chalabi,Chris Klaver,M. Duijst,Kelly Kersten,Marieke Brüggemann,Dorien Pastoors,Cheei-Sing Hau,Kim Vrijland,Elisabeth A.M. Raeven,Daphne Kaldenbach,Kevin Kos,Inna S. Afonina,Paulien Kaptein,L.R. Hoes,Willemijn S. M. E. Theelen,Paul Baas,Emile E. Voest,Rudi Beyaert,Daniela S. Thommen,Lodewyk F. A. Wessels,Karin E. de Visser,Marleen Kok +28 more
TL;DR: In this article , an unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer was performed, showing an increase in systemic and intratumoral eosinophils in patients and mice responding to ICB treatment.
Journal ArticleDOI
Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes.
Maarten P.G. Massink,Irsan E. Kooi,Saskia E. van Mil,Ekaterina S. Jordanova,Najim Ameziane,Josephine C. Dorsman,Daphne M. van Beek,J. Patrick van der Voorn,Daoud Sie,Bauke Ylstra,Carolien H.M. van Deurzen,John W.M. Martens,Marcel Smid,Anieta M. Sieuwerts,Vanja de Weerd,John A. Foekens,Ans M.W. van den Ouweland,Ewald van Dyk,Petra M. Nederlof,Quinten Waisfisz,Hanne Meijers-Heijboer +20 more
TL;DR: The identification of genomic aberrations characteristic for BRCA1‐mutated breast carcinomas could lead to a better understanding of BRCa1‐associated oncogenic events and could prove valuable in clinical testing for BRA1‐involvement in patients.